drugset / Trial / NCT04307329
Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial
Non-randomizedParallel-groupOpen-labelTreatment
Summary
In this phase II clinical trial the efficacy of the combination of monalizumab and trastuzumab is assessed in patients with metastatic or locally incurable HER2-positive breast cancer
Timeline
- Start
- 2021-03-23
- Primary completion
- 2023-01-19
- Completion
- 2024-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Monalizumab | Monoclonal antibody | 750 mg | — |
| Subject | Trastuzumab | Monoclonal antibody | 4 mg/kg | — |